scholarly journals Rehabilitation Protocols for Children with Dysfunctional Voiding

2021 ◽  
Author(s):  
Vesna D. Zivkovic ◽  
Ivona Stankovic ◽  
Lidija Dimitrijevic ◽  
Hristina Colovic ◽  
Dragan Zlatanovic ◽  
...  
Keyword(s):  
Striated Muscle ◽  
Muscle Relaxation ◽  
Botulinum Toxin Type A ◽  
Botulinum Toxin Type ◽  
Abdominal Muscle ◽  
Abdominal Muscles ◽  
Dysfunctional Voiding ◽  
Normal Children ◽  
Neurologically Normal ◽  
Tract Infections

Dysfunctional voiding is a functional voiding disorder characterized by an intermittent uroflow rate due to involuntary intermittent contractions of the striated muscle of the external urethral sphincter or pelvic floor muscles (PFMs) during voiding in neurologically normal children. Symptoms include voiding difficulties as well as urgency, voiding frequency and, in some instances, urinary incontinence and/or nocturnal enuresis. Recurrent urinary tract infections, chronic constipation and/or fecal incontinence and vesicoureteral reflux (VUR) contribute to this condition. Urotherapy is the mainstay of the treatment. It starts with education and demystification and simple behavioral modifications. Specific measures include PFM exercises with various forms of biofeedback concentrating at the recognition of PFM function and their relaxation. However, the PFMs are part of the abdominal capsule and they act in coordination with lower abdominal muscles. These muscles need to be relaxed during voiding. Diaphragmatic breathing exercises were introduced to teach children abdominal muscle relaxation. Easy to learn exercises do not require any specific equipment and can be performed at all health care levels. Children from five years of age could benefit from these exercises. In children resistant to standard treatment, botulinum toxin type A application, intermittent catheterization and surgery in children with VUR are recommended.

Botulinum Toxin Type A in Combination With Standard Urotherapy for Children With Dysfunctional Voiding

2007 ◽  
Vol 178 (6) ◽  
pp. 2599-2603 ◽  
Author(s):  
Vesna Petronijevic ◽  
Milica Lazovic ◽  
Marina Vlajkovic ◽  
Andjelka Slavkovic ◽  
Emilija Golubovic ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Dysfunctional Voiding

scholarly journals Effectiveness, safety and tolerability of botulinum toxin in focal hyperhidrosis and dynamic facial wrinkles

2019 ◽  
Vol 5 (1) ◽  
pp. 52
Author(s):  
K. Gopalakrishnan
Keyword(s):  
Botulinum Toxin ◽  
Side Effects ◽  
Muscle Relaxation ◽  
Botulinum Toxin Type A ◽  
Complete Response ◽  
Botulinum Toxin Type ◽  
Palmar Hyperhidrosis ◽  
Palmar Surface ◽  
Release Of Acetylcholine ◽  
Focal Hyperhidrosis

<p class="abstract"><strong>Background:</strong> Botulinum toxin is a potent neurotoxin that inhibits the release of acetylcholine at the neuromuscular junction thereby causing localized muscle relaxation which smoothen the overlying skin and reduces dynamic facial wrinkles. Also clinical studies suggest that intra dermal injections of botulinum toxin are effective in the treatment of palmar hyperhidrosis by blocking the excessive sympathetic cholinergic sudomotor nerve traffic to the palmar surface of the hands.</p><p class="abstract"><strong>Methods:</strong> We treated twenty patients with palmar hyperhidrosis and fifteen patients with dynamic facial wrinkles with intra dermal botulinum toxin type A.<strong></strong></p><p class="abstract"><strong>Results:</strong> Among patients treated, complete response was seen in 90% of patients with hyperhidrosis and 70% for patients with facial wrinkles. The relapse of symptoms was highly variable among patients and the average relapse was seen at 14 weeks for both the indications. No major side effects noted.</p><p class="abstract"><strong>Conclusions:</strong> Botox is an effective and highly tolerable treatment for both hyperhidrosis and facial wrinkles.</p>

scholarly journals Preoperative Progressive Pneumoperitoneum and Botulinum Toxin Type A in Patients With Large Parastomal Hernia

2021 ◽  
Vol 8 ◽  
Author(s):  
Fu-Xin Tang ◽  
Ning Ma ◽  
Xing-Xing Xie ◽  
Shuang Chen ◽  
Zhen Zong ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Parastomal Hernia ◽  
Botulinum Toxin Type A ◽  
Abdominal Cavity ◽  
Muscle Length ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Abdominal Muscle ◽  
Preoperative Progressive Pneumoperitoneum ◽  
The Mean

Background: The combination of preoperative progressive pneumoperitoneum (PPP) and botulinum toxin type A (BTA) in adjuvant treatment of large parastomal hernia (LPH) has not been reported in the previous literature.Methods: From February 2018 to June 2019, 16 patients were diagnosed with LPH in our hospital were included in this study. All patients received PPP and BTA treatment to expand abdominal volume and extend abdominal muscle before surgery. The laparoscopic Sugarbaker method was preferred for defect close.Results: Before and after PPP and BTA, the mean volume of the parastomal hernia (VPH) was 1,522 and 1,644 cc, respectively (P &lt; 0.01), and the mean volume of the abdominal cavity (VAC) was 5,847 and 9,408 cc, respectively (P &lt; 0.01). The VPH/VAC ratio was decreased by an average of 8.4% after the combination management. And the lateral abdominal muscle length was increased by an average of 4.8 cm/side (P &lt; 0.01). These patients underwent surgery successfully, and no hernia recurrence after (17.6 ± 2.4) months of follow-up.Conclusions: The combination of PPP and BTA effectively expand the abdominal volume, decrease the risk of abdominal compartment syndrome (ACS) postoperatively, and beneficial to laparoscopic repair of LPH.

scholarly journals Case of iatrogenic botulism after botulinotherapy in clinical practice

2018 ◽  
Vol 90 (11) ◽  
pp. 102-104
Author(s):  
R A Ibatullin ◽  
R V Magjanov
Keyword(s):  
Botulinum Toxin ◽  
Muscle Relaxation ◽  
Botulinum Toxin Type A ◽  
Botulinum Toxin Type ◽  
Respiratory Arrest ◽  
Good Safety Profile ◽  
Release Of Acetylcholine ◽  
Swallowing Difficulty ◽  
Motor Nerves

Injections of botulinum toxin are widely used in different medical fields, namely neurology, urology, stomatology, cosmetology, gastroenterology etc. Preparations of botulinum toxin type A (BTA) prevent the release of acetylcholine at the endings of motor nerves leading to the long-term muscle relaxation. It has been acknowledged that treatment with BTA has very good safety profile and tolerability. Extremely rare but severe complication of botulinotherapy (BT) is a condition, which is associated with generalized muscle Weakness, swallowing difficulty, respiratory arrest, and may lead to the lethal outcomes in the solitary cases. Such disorders, which present like botulism, are known as botulism-like syndrome and iatrogenic botulism. We report a clinical case of such complication in the paper. The probability of the development of such rare but severe complications necessitates certain awareness and vigilance among clinicians performing BT.

Lingual Dystonia Treated with Botulinum Toxin - A Case Report

1970 ◽  
Vol 24 (2) ◽  
pp. 75-78
Author(s):  
MA Hayee ◽  
QD Mohammad ◽  
H Rahman ◽  
M Hakim ◽  
SM Kibria
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Botulinum Toxin Type A ◽  
Botulinum Toxin Type ◽  
X Ray ◽  
Medical College ◽  
Lingual Dystonia ◽  
History Of ◽  
Chest X Ray

A 42-year-old female presented in Neurology Department of Sir Salimullah Medical College with gradually worsening difficulty in talking and eating for the last four months. Examination revealed dystonic tongue, macerated lips due to continuous drooling of saliva and aspirated lungs. She had no history of taking antiparkinsonian, neuroleptics or any other drugs causing dystonia. Chest X-ray revealed aspiration pneumonia corrected later by antibiotics. She was treated with botulinum toxin type-A. Twenty units of toxin was injected in six sites of the tongue. The dystonic tongue became normal by 24 hours. Subsequent 16 weeks follow up showed very good result and the patient now can talk and eat normally. (J Bangladesh Coll Phys Surg 2006; 24: 75-78)

Sign in / Sign up

Export Citation Format

Share Document